These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11728180)

  • 1. Free energy component analysis for drug design: a case study of HIV-1 protease-inhibitor binding.
    Kalra P; Reddy TV; Jayaram B
    J Med Chem; 2001 Dec; 44(25):4325-38. PubMed ID: 11728180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
    Karnati KR; Wang Y
    J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
    Kar P; Lipowsky R; Knecht V
    J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated molecular simulation based binding affinity calculator for ligand-bound HIV-1 proteases.
    Sadiq SK; Wright D; Watson SJ; Zasada SJ; Stoica I; Coveney PV
    J Chem Inf Model; 2008 Sep; 48(9):1909-19. PubMed ID: 18710212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state.
    Chen X; Tropsha A
    J Med Chem; 1995 Jan; 38(1):42-8. PubMed ID: 7837238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
    Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
    Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations.
    Jenwitheesuk E; Samudrala R
    BMC Struct Biol; 2003 Apr; 3():2. PubMed ID: 12675950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical free energy calculations of human immunodeficiency virus type 1 protease crystallographic complexes. II. Knowledge-based ligand-protein interaction potentials applied to thermodynamic analysis of hydrophobic mutations.
    Verkhivker GM
    Pac Symp Biocomput; 1996; ():638-52. PubMed ID: 9390264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preference-based free-energy parameterization of enzyme-inhibitor binding. Applications to HIV-1-protease inhibitor design.
    Wallqvist A; Jernigan RL; Covell DG
    Protein Sci; 1995 Sep; 4(9):1881-903. PubMed ID: 8528086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.
    Wittayanarakul K; Hannongbua S; Feig M
    J Comput Chem; 2008 Apr; 29(5):673-85. PubMed ID: 17849388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
    Lu Y; Yang CY; Wang S
    J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free energy perturbation studies on binding of A-74704 and its diester analog to HIV-1 protease.
    Rao BG; Murcko MA
    Protein Eng; 1996 Sep; 9(9):767-71. PubMed ID: 8888142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How inaccuracies in protein structure models affect estimates of protein-ligand interactions: computational analysis of HIV-I protease inhibitor binding.
    Thorsteinsdottir HB; Schwede T; Zoete V; Meuwly M
    Proteins; 2006 Nov; 65(2):407-23. PubMed ID: 16941468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examining methods for calculations of binding free energies: LRA, LIE, PDLD-LRA, and PDLD/S-LRA calculations of ligands binding to an HIV protease.
    Sham YY; Chu ZT; Tao H; Warshel A
    Proteins; 2000 Jun; 39(4):393-407. PubMed ID: 10813821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases.
    Stoica I; Sadiq SK; Coveney PV
    J Am Chem Soc; 2008 Feb; 130(8):2639-48. PubMed ID: 18225901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A semiempirical free energy force field with charge-based desolvation.
    Huey R; Morris GM; Olson AJ; Goodsell DS
    J Comput Chem; 2007 Apr; 28(6):1145-52. PubMed ID: 17274016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.
    Skálová T; Hasek J; Dohnálek J; Petroková H; Buchtelová E; Dusková J; Soucek M; Majer P; Uhlíková T; Konvalinka J
    J Med Chem; 2003 Apr; 46(9):1636-44. PubMed ID: 12699382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methodology for protein-ligand binding studies: application to a model for drug resistance, the HIV/FIV protease system.
    Dominy BN; Brooks CL
    Proteins; 1999 Aug; 36(3):318-31. PubMed ID: 10409825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.